Tagged with Pharma,

Serbia Nenad Djordjevic, managing director of Esensa, introduces the Belgrade company’s 200-strong portfolio of medical devices, food supplements, cosmetics and general use items; how it is now exporting its ‘made in Serbia’ products to geographies as diverse as Kazakhstan and Hong Kong; and how Esensa is breaking down stereotypes of what…

Serbia Ana Popovic, general manager of Serbia’s generics association, Genezis, gives her thoughts on how the generics industry has progressed in the country, what room for improvement remains, and the impact of EU succession. Where does Genezis stand in 2017 and what is keeping you busy at the moment? “The Serbian…

Canada The government of the French-speaking Canadian province of Québec stands out for undertaking healthcare reforms while appreciating the need to join hands with industry when it comes to the promotion of health innovation. “Quebec has the most aggressive approach of any province in this country [for generics pricing]” Dr. Gaétan…

Serbia Ljubiša Mitof-Višurski, general manager for AbbVie Adria, discusses the main challenges, opportunities and synergies the Adria region has to offer. He underlines the key healthcare initiatives AbbVie engages with in the region, as well as the crucial role the company plays in bringing innovative solutions to patients. Can you provide…

Lithuania Raimundas Voishka, country manager Lithuania and Belarus at Pfizer, highlights the increasing openness of the Baltic region towards innovation and stresses the commitment of Pfizer to bringing innovative as well as added-value medicines to the region. You have more than 20 years of experience in the Lithuanian pharmaceutical industry. What…

Serbia Milos Davidovic, Mylan’s country manager responsible for Serbia, Slovenia, Macedonia, and Montenegro, reveals the made-to-measure market approach that he has been implementing in the region for the past six years while highlighting the crucial role of employing a highly educated, expert workforce. What potential did Mylan see in Serbia, and…

Serbia Founder and general director of INNventa, Goran Orlic, discusses the rationale behind establishing his own company that continues to double revenues year on year. He highlights the company’s fundamental role in providing innovative solutions to Serbian patients, pharmacists and doctors. Finally, he discusses investment opportunities in the Balkans, underlining the…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…

Brazil Fernando Itzaina, president and CEO of FQM Group, originally Farmoquímica, provides inspiring insights into the threefold development vision favored by this rapidly growing pharmaceutical company, his commitment to continue exploring both organic and inorganic growth options in order to better service Brazilian patients and physicians, as well as FQM’s enduring…

Canda Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients, growing the company’s manufacturing capacity in the country and fostering the Valeant culture. What does Canada represent for Valeant today?…

Serbia Silvana Džudžević, managing director of Serbia’s leading pharma wholesale and distribution specialist, Farmalogist, introduces the evolution of the company’s operations to now include several complementary services, its numerous partnerships with international MNCs, and its utilization of digital solutions to cement the company as the partner of choice moving forward. Could…

Poland Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments. Furthermore, he highlights the company’s international strategy and strong manufacturing capabilities, both for their own treatments and in the context…